Embed Size (px)
Citation preview
Presenters:
Tracey Mumford Associate Director of Research Partnerships
Ayal Ronen Vice President, FreeMind
MJFF and FreeMind Joint Presentation
Neurological Disorders with an Emphasis on Parkinson's
July 25, 2012 FreeMind Group, LLC 2/29
FreeMind Summer SchoolFreeMind Summer School
FreeMind Group, LLC
FreeMind Group, LLC
Join us every Tuesday at Noon EDT for
the weekly FreeMind educational webinar.
Syllabus:1.SBIR/STTR2.Details of a Detailed Budget
3.Joint webinar with the Michael J. Fox Foundation on Parkinson’s and other Neurological disorders4.BARDA – mission and current funding opportunities5.Medical Devices funding opportunities6.Oncology
7.DOD – DARPA, DTRA, US Army, etc.8.Industry Academic Partnership programs
9.Bio Imaging and Bio engineering10.Biodefense and infectious diseases, NIAID
Webinar program is subject to change
3/29
4/29
5/29
6/29
7/29
8/29
9/29
10/29
11/29
12/29
13/29
14/29
July 25, 2012 FreeMind Group, LLC 15/29
� Est. 1999
� 25 Fulltime Employees
� Academia & Industry Clientele
� Extensive experience in submitting and winning large scale applications
� Over $1.5B in cumulative awards
The Global NonThe Global Non--Dilutive Funding Leader Dilutive Funding Leader
FreeMind Group, LLC
FreeMind Group, LLC
July 25, 2012 FreeMind Group, LLC 16/29
Where is the money spent?
Where is the money spent?
NIH Budget and
allocation of funding remains relatively constant between 2009
and 2011
Some Interesting StatisticsSome Interesting Statistics
20112010
$16,428,000,000
(51%)
$16,598,000,000
(51%)
Research Project
Grant
$3,020,000,000
(10%)
$3,029,000,000
(10%)
Research Centers
$3,227,000,000
(11%)
$3,459,000,000
(11%)
R&D Contracts
$3,299,000,000
(11%)
$3,285,000,000
(11%)
Intramural
ResearchAdapted from the NIH Data Book, www.report.nih.gov
July 25, 2012 FreeMind Group, LLC 17/29
Where is the money spent?
Where is the money spent?
Some Interesting StatisticsSome Interesting Statistics
Adapted from the NIH Data Book, www.report.nih.gov
July 25, 2012 FreeMind Group, LLC 18/29
NINDS Translational Research ProgramNINDS Translational Research Program
July 25, 2012 FreeMind Group, LLC 19/29
NIMH, NIA, NIAAA, NIDA,
NINDS
NIMH, NIA, NIAAA, NIDA,
NINDS
Drug Discovery for Nervous System Disorders (R01)Drug Discovery for Nervous System Disorders (R01)(PAR(PAR--1010--001)001)
Funding: Direct costs can be requested up to $500,000 per year for up to 5 years.
Scope:•To encourages research grant applications from applicant organizations directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorder.•NINDS is exclusively interested in funding proposals for the implementation of novel molecular probes (pharmacological tools) in target validation studies, and proof-of-principle preclinical studies confirming the link of a target, mechanism or phenotype with neurological disease onset or progression
Deadlines:
Next Due date:
October 5, 2012
Deadlines:
Next Due date:
October 5, 2012
July 25, 2012 FreeMind Group, LLC 20/29
NIA NIA
Alzheimer's Disease Drug Development Program (U01)Alzheimer's Disease Drug Development Program (U01)(PAR(PAR--1212--015015))
Funding: Direct costs can be requested up to $500,000 per year for up to 5 years.
Scope:•To support pre-clinical development of new therapies aimed at modifying the behavioral symptoms in AD; or delaying the onset or slowing the progression of AD, mild cognitive impairment, or age-related cognitive decline. •This program is specifically directed at projects focused on theoptimization of therapeutic leads with demonstrated activity against an intended disease target. Projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the funding period. •The program excludes clinical research and basic, mechanistic research. •Milestone-driven cooperative agreement program involving participation of NIA program staff both in the development of
the project plan and monitoring of research progress.
Deadlines:
Next Due date:
October 5, 2012
Deadlines:
Next Due date:
October 5, 2012
July 25, 2012 FreeMind Group, LLC 21/29
NIA, NINRNIA, NINR
Alzheimer's Disease Pilot Clinical Trials (R01)Alzheimer's Disease Pilot Clinical Trials (R01)(PAR(PAR--1111--100)100)
Funding: Direct costs can be requested up to $500,000 per year for up to 5 years.
Scope:
• Research grant applications for pilot clinical trials using pharmacologic and/or behavioral interventions directed toward the prevention and treatment of the cognitive and behavioral symptoms of mild cognitive impairment (MCI), Alzheimer's disease (AD), and age-related cognitive decline.
Deadlines:
Next Due date:
October 5, 2012
Deadlines:
Next Due date:
October 5, 2012
July 25, 2012 FreeMind Group, LLC 22/29
NIA, NINRNIA, NINR
NINDS SBIR Technology Transfer (SBIRNINDS SBIR Technology Transfer (SBIR--TT)TT)(PA(PA--1111--347)347)
Funding: Total funding support normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.
Scope:
• To encourages SBIR grant applications for projects to transfer technology out of the NIH intramural research labs into the private sector. If selected for SBIR funding, the SBC will be granted a royalty-free, non-exclusive internal research-use license for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that the SBC will develop the invention into a commercial product to benefit the public.
Deadlines:
Next Due date:
Aug 5, 2012Dec 5, 2012
Deadlines:
Next Due date:
Aug 5, 2012Dec 5, 2012
July 25, 2012 FreeMind Group, LLC 23/29
Risk assessment
Risk assessment
NIH Review ProcessNIH Review Process
InnovativeSignificantPI strength
Environment
RiskProbability of
Success
July 25, 2012 FreeMind Group, LLC 24/29
Key IssuesKey Issues
Maximizing Your ChancesMaximizing Your Chances
• Know the interests of the Agency
• Focus your project application
• Ask for what is necessary
• Present a complete project
• Leverage on research collaborations
Systematic Approach
July 25, 2012 FreeMind Group, LLC 25/29
Key IssuesKey Issues
Maximizing Your ChancesMaximizing Your Chances
• Different “pockets of money”
• Different size of award/success rates
• Some projects will not have the right target
• Conduct a thorough strategic assessment
Target the Right Mechanism
July 25, 2012 FreeMind Group, LLC 26/29
The Professional
Team
The Professional
Team
FreeMindFreeMind’’s NIH Teams NIH Team
� 25 full time employees
�Analysts
�Managers/Writers
� Dr. Merav Geva, FreeMind’s Director of the
Professional Department & Chief Analyst
July 25, 2012 FreeMind Group, LLC 27/29
Strategic
Assessment
Strategic
Assessment
FMG Professional ProcessFMG Professional Process
July 25, 2012 FreeMind Group, LLC 28/29
Specific ProjectSpecific Project
FMG Professional ProcessFMG Professional Process
July 25, 2012 FreeMind Group, LLC 29/29
Contact Us!Contact Us!
Thank you!Thank you!
Ayal Ronen
Vice [email protected]
(617) 648 0340
www.freemindconsultants.com
Ayal Ronen Ayal Ronen
Vice [email protected]
(617) 648 0340
www.freemindconsultants.com
Tracey Mumford
Associate Director of Research Partnerships
www.michaeljfox.org
Tracey MumfordTracey Mumford
Associate Director of Research Partnerships
www.michaeljfox.org
